PRESS RELEASE NORTH CHICAGO.

As part of a worldwide partnership with Janssen Biotech, Inc., Imbruvica is currently approved in nearly 50 countries. Imbruvica is certainly in mid – and late-stage advancement for extra hematological oncology indications, with more than 60 scientific trials underway, including 13 in Phase 3 development. Imbruvica can be in early-stage development for solid tumors. AbbVie shall market Imbruvica inthe United States. Across its oncology pipeline, AbbVie offers five late-stage assets in clinical development positioned to release within the next many years.Through monetary support, the Pfizer Australia Study Fellowships aim to encourage leaders in biomedical research to establish a career in Australia, fostering the continued development of Australia since a source of world-class scientific suggestions and innovation. The Fellowships endeavour to show that scientific research can be an important and satisfying career option. The Fellowships promote science as a significant source of innovative thinking and technical development, and as a significant contributor to our long-term economic and interpersonal well being. Winners of the Fellowship are selected by an unbiased panel of eminent Australian medical scientists. AusBiotech 2010 may be the annual meeting of AusBiotech and the premier biotechnology conference for Australia and the Asia-Pacific.